“Clinicians taking care of patients with high-risk prostate cancer being assessed for prostatectomy can use a positive [PSMA] PET scan as a true positive, whereas a negative scan cannot be used to exclude disease or inform nodal dissection,” wrote Joseph Osborne, MD, PhD, and colleagues.
“I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are…
“What we find here was that of the patients who had FGFR3 alterations, 67% of them had tumors that responded,” says Surena F. Matin, MD.
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
A decision regarding EU marketing authorization is expected by June 2024.
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…
